Terms ending in 2039
Every in-force patent on Array Biopharma Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,524,963 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS RET KINASE INHIBITORS In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 11,472,802 | Substituted Pyrazolyl[4,3-c]pyridine Compounds as Ret Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence | |
| US 11,104,676 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES In force · High confidence | Array Biopharma Inc. | In force | High confidence | |
| US 11,780,835 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES In force · High confidence | Array BioPharma Inc. | In force | High confidence | |
| US 11,603,374 | Substituted Pyrrolo[2,3-d]pyrimidines Compounds as Ret Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.